LCC03

LCC03 is a novel 5-(2′,4′-difluorophenyl)-salicylanilide derivative developed by researchers at Taipei Medical University for the treatment of metastatic castration-resistant prostate cancer (CRPC). It exerts its anticancer effects by inducing endoplasmic reticulum (ER) stress and triggering the PERK-eIF2α autophagic signaling pathway. This mechanism leads to the suppression of the AKT/mTOR pathway, increased expression of ER stress markers like GRP78 and PERK, and subsequent autophagy-mediated cell death. Preclinical studies have demonstrated that LCC03 inhibits the growth of CRPC xenografts in mouse bone models without significant systemic toxicity. Additionally, the compound has shown activity in inhibiting osteoclastogenesis, suggesting a dual therapeutic benefit in treating bone-metastatic prostate cancer by targeting both tumor cells and the bone microenvironment.

Other names

5-(2′,4′-difluorophenyl)-salicylanilide derivative